|
NZ576563A
(en)
*
|
2006-11-03 |
2012-09-28 |
Alphavax Inc |
Alphavirus and alphavirus replicon particle formulations and methods
|
|
US20090111099A1
(en)
*
|
2007-10-27 |
2009-04-30 |
Yongsheng Ma |
Promoter Detection and Analysis
|
|
US8067241B2
(en)
*
|
2009-08-26 |
2011-11-29 |
General Electric Company |
Method and apparatus for antigen retrieval process
|
|
PT2529020T
(pt)
*
|
2010-01-28 |
2018-07-30 |
Childrens Hospital Philadelphia |
Plataforma de fabrico escalável para purificação de vetor viral e vetores virais assim purificados para utilização na terapia génica
|
|
CN102985536B
(zh)
|
2010-04-14 |
2017-12-05 |
Emd密理博公司 |
生产高效价、高纯度的病毒母液的方法及使用其的方法
|
|
WO2012018628A1
(en)
|
2010-07-26 |
2012-02-09 |
Board Of Regents, The University Of Texas System |
Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
|
|
WO2012122625A1
(en)
*
|
2011-03-14 |
2012-09-20 |
National Research Council Of Canada |
Method of viral production in cells
|
|
JP6348064B2
(ja)
|
2011-11-22 |
2018-06-27 |
ザ チルドレンズ ホスピタル オブ フィラデルフィア |
効率の高いトランスジーン送達のためのウイルスベクター
|
|
EP2790737B1
(en)
*
|
2011-12-12 |
2018-11-21 |
The Children's Hospital of Philadelphia |
Large commercial scale lentiviral vector production system and vectors produced thereby
|
|
US9974850B2
(en)
|
2013-01-25 |
2018-05-22 |
Board Of Regents, The University Of Texas System |
Immunogenic compositions and uses thereof
|
|
HRP20181606T1
(hr)
|
2013-06-17 |
2018-11-30 |
De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport |
Postupci za sprječavanje agregacije virusnih komponenti
|
|
JP6567974B2
(ja)
|
2013-11-29 |
2019-08-28 |
タカラバイオ株式会社 |
アデノ随伴ウイルスの定量方法
|
|
CN114395559A
(zh)
|
2014-04-25 |
2022-04-26 |
吉尼松公司 |
高胆红素血症的治疗
|
|
EP3151866B1
(en)
|
2014-06-09 |
2023-03-08 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
WO2016004319A1
(en)
*
|
2014-07-02 |
2016-01-07 |
University Of Florida Research Foundation, Inc. |
Compositions and methods for purifying recombinant adeno-associated virus
|
|
BR112017009497A2
(pt)
|
2014-11-05 |
2018-02-06 |
Voyager Therapeutics, Inc. |
polinucleotídeos de aadc para o tratamento da doença de parkinson
|
|
US10570395B2
(en)
|
2014-11-14 |
2020-02-25 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
|
CA2967367C
(en)
|
2014-11-14 |
2023-05-16 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
HK1245326A1
(zh)
|
2014-12-12 |
2018-08-24 |
Voyager Therapeutics, Inc. |
用於生产scaav的组合物和方法
|
|
WO2016114992A2
(en)
*
|
2015-01-13 |
2016-07-21 |
Alfa Wassermann, Inc. |
Methods of purifying adeno-associated virus (aav) and/or recombinant adeno-associated virus (raav) and gradients and flow-through buffers therefore
|
|
EP3054007A1
(en)
|
2015-02-09 |
2016-08-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
|
|
EP3368054A4
(en)
|
2015-10-28 |
2019-07-03 |
Voyager Therapeutics, Inc. |
REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV)
|
|
SG11201804166YA
(en)
|
2015-11-16 |
2018-06-28 |
Res Inst Nationwide Childrens Hospital |
Materials and methods for treatment of titin-based myopathies and other titinopaties
|
|
EP4215605A1
(en)
*
|
2015-12-11 |
2023-07-26 |
The Trustees of The University of Pennsylvania |
Scalable purification method for aav8
|
|
HUE061100T2
(hu)
|
2016-03-28 |
2023-05-28 |
Ultragenyx Pharmaceutical Inc |
Adenovírus hõinaktiválásának módszerei
|
|
WO2017189964A2
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
WO2017189959A1
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
JP7066635B2
(ja)
|
2016-05-18 |
2022-05-13 |
ボイジャー セラピューティクス インコーポレイテッド |
調節性ポリヌクレオチド
|
|
RU2764587C2
(ru)
|
2016-05-18 |
2022-01-18 |
Вояджер Терапьютикс, Инк. |
Способы и композиции для лечения хореи гентингтона
|
|
US20190284576A1
(en)
*
|
2016-07-21 |
2019-09-19 |
Spark Therapeutics, Inc. |
SCALABLE HIGH RECOVERY METHODS FOR PRODUCING HIGH YIELD RECOMBINANT ADENO-ASSOCIATED VIRAL (rAAV) VECTOR AND RECOMBINANT ADENO-ASSOCIATED VIRAL (rAAV) VECTORS PRODUCED THEREBY
|
|
EP3510161A4
(en)
|
2016-08-23 |
2020-04-22 |
Akouos, Inc. |
COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING DEFICIENCY IN A HUMAN SUBJECT
|
|
US11298041B2
(en)
|
2016-08-30 |
2022-04-12 |
The Regents Of The University Of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
|
EP3293203A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
EP3293260A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
EP3293259A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
AU2017322376B2
(en)
|
2016-09-12 |
2023-08-17 |
Association Institut De Myologie |
Acid-alpha glucosidase variants and uses thereof
|
|
EP3512939A1
(en)
|
2016-09-16 |
2019-07-24 |
Leukocare AG |
A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
|
|
PL3534922T3
(pl)
|
2016-11-04 |
2024-08-19 |
Takeda Pharmaceutical Company Limited |
Preparaty wirusa związanego z adenowirusem
|
|
US10626376B2
(en)
|
2016-11-14 |
2020-04-21 |
St. Jude Children's Research Hospital |
Method for isolating and purifying adeno-associated virus particles using salt
|
|
US10294452B2
(en)
*
|
2016-11-22 |
2019-05-21 |
Dao-Yao He |
Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells
|
|
US11357735B2
(en)
|
2017-02-01 |
2022-06-14 |
Centre National De La Recherche Scientifique |
Particles and compositions comprising the same for transfection
|
|
EP3592848A1
(en)
|
2017-03-10 |
2020-01-15 |
Genethon |
Treatment of glycogen storage disease iii
|
|
SG11201909868YA
(en)
|
2017-05-05 |
2019-11-28 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease
|
|
EP3618839A4
(en)
|
2017-05-05 |
2021-06-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
JP7229989B2
(ja)
|
2017-07-17 |
2023-02-28 |
ボイジャー セラピューティクス インコーポレイテッド |
軌道アレイガイドシステム
|
|
AU2018311069A1
(en)
|
2017-08-03 |
2020-02-20 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of AAV
|
|
EP3687582A4
(en)
|
2017-09-29 |
2021-07-14 |
Voyager Therapeutics, Inc. |
RESCUE OF CENTRAL AND PERIPHERAL NEUROLOGICAL PHENOTYPE OF FRIEDREICH ATAXIA BY INTRAVENOUS ADMINISTRATION
|
|
US20200237799A1
(en)
|
2017-10-16 |
2020-07-30 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
TW202413649A
(zh)
|
2017-10-16 |
2024-04-01 |
美商航海家醫療公司 |
肌萎縮性脊髓側索硬化症(als)之治療
|
|
EP3707264A1
(en)
|
2017-11-08 |
2020-09-16 |
Avexis Inc. |
Means and method for preparing viral vectors and uses of same
|
|
JP2021505610A
(ja)
*
|
2017-12-05 |
2021-02-18 |
アプライド ジェネティック テクノロジーズ コーポレイション |
ウイルス粒子のための製剤最適化
|
|
SG11202006722RA
(en)
|
2018-01-31 |
2020-08-28 |
Res Inst Nationwide Childrens Hospital |
Gene therapy for limb-girdle muscular dystrophy type 2c
|
|
JP7467356B2
(ja)
|
2018-02-07 |
2024-04-15 |
ジェネトン |
ハイブリッド調節要素
|
|
US20210010028A1
(en)
|
2018-03-06 |
2021-01-14 |
Voyager Therapeutics, Inc. |
Insect cell manufactured partial self-complementary aav genomes
|
|
AU2019257755A1
(en)
|
2018-04-27 |
2020-11-12 |
Voyager Therapeutics, Inc. |
Methods for measuring the potency of AADC viral vectors
|
|
JP2021523914A
(ja)
|
2018-05-15 |
2021-09-09 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
パーキンソン病を治療するための組成物および方法
|
|
WO2019222441A1
(en)
|
2018-05-16 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Aav serotypes for brain specific payload delivery
|
|
WO2019222444A2
(en)
|
2018-05-16 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Directed evolution
|
|
US12228571B2
(en)
|
2018-06-08 |
2025-02-18 |
Novartis Ag |
Cell-based assay for measuring drug product potency
|
|
EP3814514A1
(en)
|
2018-06-29 |
2021-05-05 |
Research Institute at Nationwide Children's Hospital |
Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a
|
|
SG11202012044QA
(en)
|
2018-06-29 |
2021-01-28 |
Wuhan Neurophth Biological Tech Limited Company |
Compositions and methods for treating leber's hereditary optic neuropathy
|
|
CA3103963A1
(en)
|
2018-07-02 |
2020-01-09 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
|
|
US20210163990A1
(en)
*
|
2018-07-11 |
2021-06-03 |
Baxalta Incorporated |
Aav compositions
|
|
US20210355454A1
(en)
|
2018-07-24 |
2021-11-18 |
Voyager Therapeutics, Inc. |
Systems and methods for producing gene therapy formulations
|
|
CA3107572A1
(en)
|
2018-08-08 |
2020-02-13 |
Genethon |
Mini-gde for the treatment of glycogen storage disease iii
|
|
AU2019319976B2
(en)
*
|
2018-08-10 |
2025-08-14 |
Regenxbio Inc. |
Scalable method for recombinant AAV production
|
|
AU2019323434A1
(en)
|
2018-08-20 |
2021-02-25 |
Wuhan Neurophth Biotechnology Limited Company |
Compositions and methods for treating leber's hereditary optic neuropathy
|
|
EP3856762A1
(en)
|
2018-09-28 |
2021-08-04 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
TW202035689A
(zh)
|
2018-10-04 |
2020-10-01 |
美商航海家醫療公司 |
測量病毒載體粒子的效價及強度之方法
|
|
SG11202107645RA
(en)
|
2019-01-18 |
2021-08-30 |
Voyager Therapeutics Inc |
Methods and systems for producing aav particles
|
|
US12377170B2
(en)
|
2019-02-26 |
2025-08-05 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus vector delivery of β-sarcoglycan and the treatment of muscular dystrophy
|
|
CN113747926A
(zh)
|
2019-04-08 |
2021-12-03 |
吉尼松公司 |
用于肌肉表达的杂合启动子
|
|
TW202103718A
(zh)
*
|
2019-04-19 |
2021-02-01 |
美商銳進科斯生物股份有限公司 |
腺相關病毒載體調配物及方法
|
|
BR112021020888A2
(pt)
|
2019-04-19 |
2021-12-21 |
Genethon |
Terapia gênica de doenças hipofosfatêmicas relacionadas a fator de crescimento fibroblástico 23
|
|
TW202106879A
(zh)
|
2019-04-29 |
2021-02-16 |
美商航海家醫療公司 |
於生物反應器中生產經桿狀病毒感染之昆蟲細胞(biic)之系統及方法
|
|
EP4004213A1
(en)
|
2019-07-25 |
2022-06-01 |
Novartis AG |
Regulatable expression systems
|
|
WO2021030125A1
(en)
|
2019-08-09 |
2021-02-18 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
EP4013436A1
(en)
|
2019-08-14 |
2022-06-22 |
Leukocare Ag |
Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
|
|
US11155835B2
(en)
|
2019-08-19 |
2021-10-26 |
The Catholic University Of America |
Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells
|
|
US11401530B2
(en)
|
2019-08-19 |
2022-08-02 |
The Catholic University Of America |
Bacteriophage-based artificial viruses for human genome remodeling
|
|
DK4017871T5
(da)
|
2019-08-21 |
2024-08-05 |
Res Inst Nationwide Childrens Hospital |
Adenoassocieret virusvektoradministration af alfa-sarcoglycan og behandling af muskeldystrofi
|
|
EP4022070A1
(en)
|
2019-08-26 |
2022-07-06 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
AU2020362119A1
(en)
|
2019-10-07 |
2022-05-26 |
Regenxbio Inc. |
Adeno-associated virus vector pharmaceutical composition and methods
|
|
WO2021078834A1
(en)
|
2019-10-22 |
2021-04-29 |
Genethon |
Chimeric acid-alpha glucosidase polypeptides and uses thereof
|
|
CN114555808A
(zh)
|
2019-10-22 |
2022-05-27 |
吉尼松公司 |
嵌合多肽及其用途
|
|
CN113025633B
(zh)
|
2019-12-09 |
2024-08-27 |
武汉纽福斯生物科技有限公司 |
编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
|
|
KR102167829B1
(ko)
*
|
2020-02-10 |
2020-10-20 |
주식회사 이노테라피 |
아데노연관바이러스용 안정화제 및 이를 이용한 아데노연관바이러스의 안정화 방법
|
|
WO2021168362A1
(en)
|
2020-02-21 |
2021-08-26 |
Akouos, Inc. |
Compositions and methods for treating non-age-associated hearing impairment in a human subject
|
|
WO2021236908A2
(en)
|
2020-05-20 |
2021-11-25 |
Biomarin Pharmaceutical Inc. |
Use of regulatory proteins for the production of adeno-associated virus
|
|
EP3913060A1
(en)
|
2020-05-22 |
2021-11-24 |
Genethon |
Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapy
|
|
CA3185729A1
(en)
*
|
2020-06-02 |
2021-12-09 |
Janssen Biotech, Inc. |
Materials and methods for viral purification
|
|
EP4192514A1
(en)
|
2020-08-06 |
2023-06-14 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
AU2021320395A1
(en)
*
|
2020-08-07 |
2023-04-13 |
Janssen Biotech, Inc. |
Formulations for highly purified viral particles
|
|
EP4200410A1
(en)
|
2020-08-24 |
2023-06-28 |
Genethon |
C-terminal truncated gde for the treatment of glycogen storage disease iii
|
|
AU2021372262B9
(en)
|
2020-11-02 |
2025-05-15 |
Biomarin Pharmaceutical Inc. |
Process for enriching adeno-associated virus
|
|
CA3199661A1
(en)
|
2020-12-09 |
2022-06-16 |
Mario Amendola |
Lysosomal acid lipase variants and uses thereof
|
|
US20240141378A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
US20240141377A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
US20240240204A1
(en)
*
|
2021-05-07 |
2024-07-18 |
Board Of Regents, The University Of Texas System |
Methods and compositions for transport, storage, and delivery of adeno-associated viral vector and other molecules
|
|
WO2023012313A1
(en)
|
2021-08-04 |
2023-02-09 |
Genethon |
Hybrid promoters for gene expression in muscles and in the cns
|
|
EP4402265A1
(en)
|
2021-09-16 |
2024-07-24 |
Novartis AG |
Novel transcription factors
|
|
US12285497B2
(en)
|
2021-10-15 |
2025-04-29 |
Research Institute At Nationwide Children's Hospital |
Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy
|
|
WO2023073526A1
(en)
|
2021-10-25 |
2023-05-04 |
Novartis Ag |
Methods for improving adeno-associated virus (aav) delivery
|
|
EP4511392A1
(en)
|
2022-03-17 |
2025-02-26 |
Innoskel |
Polynucleotides encoding the alpha-1 chain of human type ii collagen and methods of their use
|
|
WO2023175585A1
(en)
|
2022-03-17 |
2023-09-21 |
Innoskel |
Hybrid promoters and their use in osteolysis syndrome
|
|
CN118974284A
(zh)
|
2022-05-06 |
2024-11-15 |
诺华股份有限公司 |
新型重组aav vp2融合多肽
|
|
WO2023237731A1
(en)
|
2022-06-09 |
2023-12-14 |
Genethon |
N-terminal truncated gde for the treatment of glycogen storage disease iii
|
|
WO2024054983A1
(en)
|
2022-09-08 |
2024-03-14 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
TW202426017A
(zh)
*
|
2022-11-24 |
2024-07-01 |
俄羅斯聯邦商拜奧卡德聯合股份公司 |
非包膜病毒的藥物組合物
|
|
WO2025003477A1
(en)
|
2023-06-29 |
2025-01-02 |
Genethon |
N-terminal truncated glycogen debranching enzymes for the treatment of glycogen storage disease iii
|
|
EP4606892A1
(en)
|
2024-02-23 |
2025-08-27 |
Merck Patent GmbH |
Methods for the production of viral particles
|